Pfizer starts the Phase I trial of biosimilar adalimumab

June 14, 2013 10:37 AM

Pfizer, the big pharma giant has started investing in biosimilars as you already know.Last year, we have informed you about the initiation of rituximab biosimilar trial and they are also carrying out a trial for a biosimilar version of trastuzumab. 

This time, according to clinicaltrials.gov, we can see that, Pfizer has started recruiting patients for adalimuma biosimilar phase I trial. The reference medicine is Humira, which is used in several indications including rheumatoid arthritis.

This healthy volunteers study will evaluate 210 subjects who will receive a single sub-cutaneous dose of PF-06410293 or adalimumab (United States) or adalimumab (European Union). This study will involve sampling and pharmacokinetics evaluation of drug levels following administration of PF-06410293 and the licensed adalimumab products.

 

Source: ClinicalTrials.gov

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)


Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?

Suggestions?

Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!